Market Performance - The Dow Jones Industrial Average increased by 527.88 points (1.1295%) to reach 47262.49, with Dow Futures up 538.00 points (1.1466%) at 47460.00, marking a strong market performance [1] - The Dow, S&P 500, and Nasdaq all achieved new record highs, driven by the release of cooler-than-expected September inflation figures [1] Economic Data - The Consumer Price Index (CPI) report indicated a year-over-year price increase of 3.0%, slightly below the anticipated 3.1%, which has boosted investor optimism for continued Federal Reserve interest rate cuts [1] Company Performance - IBM led the gains among Dow components, surging 8.10% to $308.16 [2] - Financial sector stocks performed well, with Goldman Sachs rising 4.00% to $781.94 and JPMorgan Chase increasing 2.48% to $302.16 [2] - Technology companies also saw positive movement, with Nvidia up 1.77% and Amazon gaining 1.76% [2] Declining Stocks - Despite the overall market strength, some Dow constituents faced declines, including Honeywell down 1.83% to $216.29 and 3M decreasing 1.79% to $168.63 [3] - Johnson & Johnson's shares fell 1.20% to $190.14, while Disney recorded a 1.02% drop to $111.87 [3]

Market Trends - The recent launch of the meme ETF has coincided with a peak in the meme index, similar to its previous launch in November 2021 [2] - Parabolic moves in asset classes tend to revert, and there are signs of weakness in non-parabolic areas of the market [3][5] - The market has gone 121 straight trading days without testing the 50-day moving average, with historical data suggesting a likely test of this average soon [5][6] Defensive Sectors - There is a rotation into more defensive parts of the market, particularly in REITs and healthcare, which are showing breakout patterns [8] Earnings Outlook - A significant slate of earnings from major companies is expected next week, which could be a critical factor for the overall market [9] Gold Market Analysis - Gold was approximately 28-30% above the 200-day moving average at its peak, marking the widest spread in 20 years, and is currently experiencing a pullback [11] - A potential further decline for gold is anticipated to test the 50-day moving average, although the structural uptrend for metals remains intact [12][13] - Despite the recent pullback, gold is still up more than 9% over the past month [13]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of LifeMD, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during a specified class period [1][3]. Summary by Sections Class Period and Allegations - The class period for the lawsuit is from May 7, 2025, to August 5, 2025 [3]. - Allegations include that LifeMD's management overstated the company's competitive position and raised 2025 guidance without properly accounting for rising customer acquisition costs, particularly in the RexMD segment and for obesity treatment drugs like Wegovy and Zepbound [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by October 25, 2025, to potentially become lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [5].

I'm not going anywhere, right. I I got all the money I need. The idea of me I mean screwing up the healthcare industry, that's better than putting your name on a building.is better than anything else because there's nobody in the history of everybody in this country who likes the way the cost of healthcare is and the cost of medication. ...

Investment Rating - The report indicates a positive investment sentiment with a focus on buying the dip in US equities, particularly in single stocks, which saw significant inflows [9][18]. Core Insights - Institutional and retail clients were net buyers of US equities, with a notable $4.1 billion inflow into single stocks, marking the fifth highest weekly inflow since 2008 [9][18]. - The report highlights a shift back to large-cap stocks, with inflows observed across all market cap sizes, particularly in Communication Services and Health Care sectors [9][18]. - Hedge funds continued to sell US equities for the fifth consecutive week, contrasting with the buying behavior of institutional and retail clients [9][18]. Summary by Sections Client Flows - Institutional clients led the buying activity, marking the largest weekly inflow since November 2022, while retail clients also participated after a period of selling [9][18]. - Hedge funds were the largest net sellers, with cumulative flows showing a significant outflow trend [5][22]. Sector Performance - Inflows were recorded across all 11 sectors, with Communication Services and Health Care leading the way, alongside notable inflows in the Energy sector [9][18]. - The report notes that clients sold equity ETFs for a second week, with outflows primarily from Tech and Materials sectors, while defensive sectors like Health Care and Real Estate saw inflows [9][18]. Size Segmentation - All market cap segments (large, mid, small) experienced inflows, with small caps showing resilience with inflows in five of the last seven weeks [9][18]. - The report indicates a preference for small-cap and value ETFs, contrasting with the outflows from large and mid-cap ETFs [9][18]. Corporate Buybacks - Corporate buybacks have slowed but are expected to pick up during the earnings season, with a focus on Tech and Financials dominating the buyback activity over the last three months [9][18].

Joining us now, a Democratic Congressman from Maryland, Glenn Ivy, who represents about 65,000 federal workers. Congresswoman, welcome. Um, you just heard AOC there.Do you agree with her that Democrats are looking for a long-term solution. They don't want any kind of a quick band-aid fix. Well, I think her uh political analysis is right there for sure.And couple points in addition, keep in mind that when it came to extending the tax cuts for the wealthiest Americans, the House Republicans and the Senate Rep ...

Business Expansion - One Medical is expanding into pediatric care [1] - One Medical launches a new pay-per-visit virtual health service for children ages 2 to 11 [1] Pricing and Services - Message-based visits start at $29 [1] - Video calls start at $49 [1] - The service treats common conditions like pink eye, eczema [1]

Core Insights - The Healthtech sector is experiencing a significant shift towards AI-enabled provider operations, which accounted for 44% of overall Healthtech investment in 2025, marking the highest investment levels since 2022 [1][2] - A total of $5.5 billion has been invested in healthcare provider operations, with projections indicating a full-year investment of $8.25 billion, surpassing the previous record of $7.8 billion set in 2021 [1][6] - The focus of investment is shifting from clinical care to operational tools, as AI is utilized to enhance efficiency in healthcare delivery [1][4] Investment Trends - Provider operations have seen a dramatic increase in investment, rising from 19% of Healthtech investment four years ago to nearly 50% in 2025 [1][6] - Alternative care investment has decreased significantly, accounting for only 9% of Healthtech investment in 2025, down from 42% in 2021 [1][6] - The total expected investment in Healthtech by the end of 2025 is projected to reach $18.5 billion [6] M&A Activity - There have been 32 mergers and acquisitions (M&A) deals in provider operations in 2025, with consolidation becoming a key exit strategy for investors [6] - 52% of the deals in 2025 have involved AI technologies, indicating a strong trend towards integrating AI in Healthtech [6] Valuation Insights - Generalist investors have added a valuation premium of 22% to mega-deals, which represent 38% of total Healthtech investment this year [6] - Seed-stage AI valuations have increased by approximately 42% since 2021, reflecting growing confidence in AI solutions [6] Trust in AI - Physicians express a high level of trust in AI for work efficiency (75%), but show significant concern regarding patient privacy, with only 15% trusting AI in this aspect [6]

Market Overview - U.S. stock futures were higher, with Dow futures gaining over 100 points on Thursday [1] Company-Specific Movements - Satellogic Inc. (NASDAQ:SATL) shares fell 13.1% to $3.60 in pre-market trading following a proposed public offering [1] - American Battery Technology Company (NASDAQ:ABAT) shares dipped 23.9% to $6.81 after the DOE terminated a grant [3] - Hyperfine, Inc. (NASDAQ:HYPR) shares decreased 14.1% to $1.89 due to preliminary third-quarter revenue results falling below estimates and a proposed public offering [3] - Omeros Corporation (NASDAQ:OMER) shares declined 9.2% to $9.45 after a significant 154% increase the previous day following Novo Nordisk's acquisition of its global rights to Zaltenibart [3] - Hewlett Packard Enterprise Company (NYSE:HPE) tumbled 8.6% to $22.85 despite reporting record revenue driven by AI demand, as restructuring costs compressed profit margins [3] - NIO Inc. (NYSE:NIO) fell 8.5% to $6.24 in pre-market trading [3] - Inventiva S.A. (NASDAQ:IVA) declined 7.5% to $5.06 after a 10% gain the previous day [3] - Bitfarms Ltd. (NASDAQ:BITF) fell 4.6% to $6.17 after announcing a $300 million convertible senior notes offering [3] - Rigetti Computing, Inc. (NASDAQ:RGTI) shares fell 4.8% to $53.66 following CEO Subodh K. Kulkarni's sale of 1,000,000 shares, raising concerns about leadership commitment [3] - Datavault AI Inc. (NASDAQ:DVLT) slipped 4.8% to $2.00 in pre-market trading [3]

Group Financial Performance and Strategy - Merck aims to drive sustainable value creation as a leading science & technology company[7] - The company is actively managing its portfolio, focusing on attractive markets and solid competitive positions, with >80% of businesses in each category[10, 11] - Merck confirms M&A guardrails and financial discipline, with ongoing scouting for further M&A to accelerate growth[18] - The company is committed to topline growth and margin expansion mid-term[72] - Merck is on track to meet its 2025 guidance and has a positive early indication for 2026, with an expected EBITDA pre margin of ~29% in 2025[69, 70] Key Growth Drivers - Key growth drivers explain up to 80% of future growth, focusing on secular growth markets[20] - Process Solutions market segment continues to grow at a 9% to 10% CAGR[37] - Semiconductor Solutions contribute over 80% to Electronics sales mid-term[50] - Healthcare mid-term growth ambition is raised, driven by Rare Diseases uptake, targeting LSD to MSD organic sales growth (CAGR in %)[46] Life Science Strategy - Life Science is centering the business on three distinct go-to-market approaches: Process Solutions (~€35 billion), Advanced Solutions (~€47 billion), and Discovery Solutions (~€29 billion)[32]